Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 10/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MRGPRX1 | Q96LB2 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3255543 | 0.87 | KMT2A (0.46) | KMT2ALMNAHPGD | |
| SCHEMBL8263151 | 0.81 | SLC6A9 (0.43) | SLC6A9KMT2AHPGDALDH1A1 | |
| SCHEMBL3257622 | 0.81 | ALDH1A1 (0.38) | SLC6A9KMT2ALMNAHPGDALDH1A1 | |
| SCHEMBL3237287 | 0.79 | SLC6A9 (0.45) | SLC6A9LMNAHPGD | |
| SCHEMBL3232935 | 0.79 | SLC6A9 (0.47) | SLC6A9KMT2ALMNA | |
| SCHEMBL3236131 | 0.78 | ALDH1A1 (0.41) | SLC6A9LMNAHPGDALDH1A1KDM4E | |
| SCHEMBL4367407 | 0.78 | NSD2 (0.48) | SLC6A9ALDH1A1KDM4E | |
| SCHEMBL3244891 | 0.78 | SLC6A9 (0.59) | SLC6A9 | |
| SCHEMBL4356991 | 0.78 | SCN9A (0.49) | SLC6A9KMT2ALMNAHPGD | |
| SCHEMBL4355261 | 0.78 | CXCR5 (0.44) | SLC6A9KMT2ALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137428-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137428-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| US-20100137428-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LIMITED | 2010-06-03 | — | — | US | disclosed |
| EP-1833811-B1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | GLAXO GROUP LTD (GB) | 2010-06-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137428-A1 | OXYGEN CONTAINING HETEROCYCLES AS GLYCINE TRANSPORTER INHIBITING COMPOUNDS | SLC18A2, SLC1A2, SLC6A3 | SLC6A9 37/4885KMT2A 1688/4885MRGPRX1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.